YOKOHAMA, February 12, 2019 – ARTham Therapeutics, Inc., a clinical st
Deliver “medicines that matter” to improve patient health and contribute to enhanced quality of life. At ARTham Therapeutics, we will create value by developing innovative medicines that are disease modifying and improve patient health.
ARTham Therapeutics Inc., is a clinical stage biopharmaceutical company that will deliver ‘medicines that matter’ for patients. Our goal is to create innovative medicines that are disease modifying and satisfy significant unmet medical need. To deliver on cost and time efficiency, ARTham will run a virtual R&D operating model that seeks innovation through the best academic and business partners.
Former VP, Head of Innovation & Entrepreneurship,Extra Value Generation Drug
Discovery Unit, Takeda Pharmaceuticals;
Global Head of Discovery, Nycomed, Zurich;
Director, Chemistry & Neuroscience
Therapeutic Area, Parke-Davis/Warner Lambert and Pfizer; Smith Kline & French Labs (now GSK), Sandoz (now Novartis); Adjunct Associate Professor, University of Michigan, Ann Arbor
Expert in drug discovery/early development
medicinal chemistry, CMC, informatics, drug repositioning
Visiting lecturer, Oita University
Visiting fellow, Yokohama City University
Former Sr Director, Innovation & Entrepreneurship, Extra Value Generation Drug Discovery Unit,
Takeda Pharmaceuticals.; Research Fellow, Merck Research Labs, USA; Visiting Fellow, Florida State University
Expert in pharmacology, translational medicine, drug repositioning
Professor, Clinical Pharmacology, Oita University;
Adjunct Professor, Osaka University
Former Director and International Fellow, Clinical Research, Merck Research Labs, USA;
Visiting Research Scholar University of California at San Francisco (UCSF)
Expert in clinical pharmacology, translational medicine,
early clinical development
Visiting scholar, Oita University
Former Clinical Scientist, Takeda Gastrointestinal Therapeutic Area Unit, Boston, USA; Principal Scientist, Extra Value Generation Drug Discovery Unit, Oncology Drug Discovery Unit, Takeda Pharmaceuticals
Expert in clinical science, pharmacology, endocrinology, oncology, drug repositioning
Our passion is to unravel hidden value of preclinical and clinical assets via cutting edge science . This will be driven by deeper understanding of disease etiology, relevance to target mechanisms and optimal modality to deliver drugs that ultimately help patients to be healthy.
NASH is a progressive form of NAFLD (Non Alcoholic Fatty Liver Disease) with patients that advance to fibrosis due to inflammatory processes that result into cirrhosis or liver cancer. There is no approved pharmacotherapy for NASH.
Although it is difficult to obtain an accurate estimate of NASH prevalence given the fact that NASH is a silent disease, there is a report that the global prevalence of NAFLD is as high as one billion. In the United States, NAFLD is estimated to be the most common cause of chronic liver disease, affecting between 80 and 100 million individuals, among whom nearly 25% progress to NASH (World J Gastroenterol 2017, 23: 8263-8276) .
Analysts predict NASH drug market could reach anywhere between $25-$35 billion by 2025 (Reuters BUSINESS NEWS, APRIL 24, 2017; BusinessWire February 12, 2018)
Vascular malformations are benign (non-cancerous) lesions that are present at birth, but may become visible for weeks or months after birth. Unlike hemangiomas, vascular malformations do not have a growth cycle and then regress but instead continue to grow slowly throughout life. Most vascular malformations are sporadic (occurring by chance), though some are inherited in a family as an autosomal dominant trait.